Stockholm, Sweden

ESTRO 2026

Session

Tuesday
May 19
11:00 - 12:15
A3
Oligo-strategies in female cancer: Breast and gynaecological at the frontier of SABR
Fran Duane, Ireland;
Sorina Alexandra Niculescu , Romania
This session will focus on the role of metastases-directed therapy in the form of stereotactic ablative body radiotherapy in the treatment of oligometastatic breast and gynaecological malignancies. Ongoing and future studies will be summarised. Selection criteria will be presented emphasising the importance of considering varying biological subtypes. Decision-making around how to integrate local therapy with systemic therapies will be addressed. Importantly this symposium will include the patient's perspective to better understand what is most important to patients in terms of treatment goals and unmet needs.
Symposium
Clinical
11:00 - 11:25
SABR for oligometastatic gynaecological cancers: Where do we stand?
Gabriella Macchia, Italy
-5402
11:25 - 11:50
SABR in oligometastatic breast cancer: Integrating local therapy into systemic management
Barbro Linderholm, Sweden
-5404
11:50 - 12:15
SABR oligometastases: Understanding patients’ perspectives
Sukhdeep Nagpal, United Kingdom
-5403